Replies to post #4763 on GTC Biotherapeutics (fka GTCB)

[DewDiligence]

I think we all agree that the ART-123 results in the published paper were not great. But the results from the phase-2b trial just starting could turn out better, so it’s premature, IMO, to write off ART-123 just yet. Regards, Dew

[vinmantoo]

I think you are missing the point of writing a scientific paper. The authors are doing research and then writing up the results. You will always emphasize the most positive results, in this case bleeding, and then mention the data that was not significant later on, in this case the affect on mortality. It really isn't an attempt to deceive or bury data if you look at it strictly from a scientific viewpoint. Of course, as an investor, you might have a different attitude.